Ipsilateral axillary lymph node metastasis is common, while contralateral axillary lymph node metastasis (CAM) is uncommon. This report is of a patient that presented with a recurrence of left breast cancer and synchronous CAM, with a distant history of left breast conserving surgery and axillary dissection for invasive carcinoma. The CAM was confirmed following a non-routine lymphoscintigraphy and sentinel lymph node biopsy. This highlights the possibility of CAM representing as locoregional disease rather than advanced stage IV disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968533 | PMC |
| http://dx.doi.org/10.1136/bcr-2022-248741 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
De-escalation of surgical and radiation treatment in elderly luminal breast cancer patients, single institution report and review of the evidence.
World J Surg Oncol
January 2025
Institute of Oncology, Tel Aviv Sourasky Medical Center, Weizmann St 6, Tel Aviv, Israel.
Background: De-intensification of anti-cancer therapy without significantly affecting outcomes is an important goal. Omission of axillary surgery or breast radiation is considered a reasonable option in elderly patients with early-stage breast cancer and good prognostic factors. Data on avoidance of both axillary surgery and radiation therapy (RT) is scarce and inconclusive.
View Article and Find Full Text PDFA machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.
Biomark Res
January 2025
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, P.R. China.
Background: Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using a machine learning approach to identify FL patients at high risk of POD24.
Methods: A cohort of 1,938 FL patients (FL1-3a) from seventeen centers nationwide in China was randomly divided into training and internal validation sets (2:1 ratio).
A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma.
World J Surg Oncol
January 2025
Summit Medical Group, Bend, OR, USA.
Background: National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5-10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-GEP) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.
Methods: The i31-GEP SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322).
Ultrasonographic accuracy in evaluating response of clipped lymph nodes in targeted axillary dissection in breast cancer.
Sci Rep
January 2025
Department of Medical Pathology, Ege University Faculty of Medicine, Ege University Hospital, Bornova, İzmir, Turkey.
This study aimed to evaluate the diagnostic accuracy of ultrasonography in assessing the response of clipped axillary lymph nodes to neoadjuvant chemotherapy. Between February 2022 and September 2023, 43 patients who underwent axillary lymph node marking for targeted axillary dissection were retrospectively analyzed. Ultrasonography parameters such as the number, size, shape, cortical thickness, hilum status, and treatment response of the clipped lymph node were assessed.
View Article and Find Full Text PDFOligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?
Curr Oncol Rep
January 2025
Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Purpose Of The Review: This narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial design in patients with de-novo esophagogastric oligometastatic disease (OMD).
Recent Findings: The IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junction cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only. The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!